89Bio Inc. Sees Analyst Optimism Amid Stock Volatility and Strategic Focus on Liver Treatments
89Bio Inc.’s stock price has seen fluctuations, with a recent target price adjustment to $55 by Cantor Fitzgerald, amidst the company’s focus on liver and metabolic disorder treatments.
2 minutes to read